Ipca Laboratories Limited
IPCALAB
Rang in Aktien
#3403
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Aktienkurs
$20.02
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$5.08B
Veränderung (1 Tag)
-1.65%
Veränderung (1 Jahr)
38.46%
Land
IN
Handel Ipca Laboratories Limited (IPCALAB)
Kategorie
Healthcare
P/B-Verhältnis für Ipca Laboratories Limited (IPCALAB)
P/B-Verhältnis zum October 2026 TTM: 6.01
Laut den neuesten Finanzberichten und dem Aktienkurs von Ipca Laboratories Limited beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 6.01. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 4.97.
P/B-Verlauf für Ipca Laboratories Limited von 2005 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 6.01 | 18.32% |
| 2025 | 5.08 | 2.13% |
| 2024 | 4.97 | 41.30% |
| 2023 | 3.52 | -28.52% |
| 2022 | 4.92 | -3.99% |
| 2021 | 5.13 | 5.76% |
| 2020 | 4.85 | 23.20% |
| 2019 | 3.94 | 26.08% |
| 2018 | 3.12 | -2.65% |
| 2017 | 3.21 | -1.40% |
| 2016 | 3.25 | -10.50% |
| 2015 | 3.63 | -33.22% |
| 2014 | 5.44 | 27.37% |
| 2013 | 4.27 | 26.78% |
| 2012 | 3.37 | -6.01% |
| 2011 | 3.58 | -7.79% |
| 2010 | 3.89 | 195.76% |
| 2009 | 1.31 | -49.85% |
| 2008 | 2.62 | -17.46% |
| 2007 | 3.18 | 34.15% |
| 2006 | 2.37 | 2.83% |
| 2005 | 2.30 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -16.13% |
IN
|
